CSPC Group (01093.HK) cancelled 26.628 million shares on May 3

Gelonghui, May 3, 丨 Shiyao Group (01093.HK) announced that on May 3, 2024, 26.628 million shares have been cancelled.

Gelonghui Finance04:33 ET

China's Automakers Must Adapt Quickly on the EV Boom in the Face of Regulatory Scrutiny Abroad

Adoption of battery and hybrid-powered cars has surged in China, but an onslaught of new models has fueled a price war, while regulatory scrutiny grows abroad.

CNBC03:06 ET

[Broker Focus] CMB International cuts target price of BYD Electronics (00285) by 2.92%, indicating that the first quarter results are in line with expectations

Jinwu Financial News | According to CMB International Development Research Report, BYD Electronics' (00285) revenue/profit increased 38%/33% year-on-year in the first quarter of 2024, mainly due to Android and Apple orders, Jeep's parts business, and stable automotive/smart product business. The gross margin of 1Q24 was 6.9%, down 0.8 ppt year on year. The higher profit margin of the component/automobile/new intelligence business was offset by an increase in the sales mix of the assembly business. Overall, 1Q24's results were steady and in line with expectations, despite seasonal and RMB influences. Looking ahead to 2024, management is looking forward to the recovery of high-end Android,

金吾財訊01:05 ET

YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings May Just Be The Starting Point

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shar

Simply Wall St20:19 ET

Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%

Sihuan Pharmaceutical Holdings Group (HKG:0460) said its New Drug Application (NDA) to China's National Medical Products Administration (NMPA) was accepted for the lung cancer drug Dexitinib tablets,

MT NewswiresMay 2 03:37 ET

Sihuan Pharmaceutical (00460.HK): Xuanzhu Biotech independently developed a Class 1 innovative drug “daxitinib tablets” and applied for marketing to the State Drug Administration and accepted

On May 2, Ge Longhui Pharmaceutical (00460.HK) announced that the Class 1 innovative anti-tumor drug “daxitinib tablets” (product code: XZP-3621) independently developed by Xuanzhu Biotechnology Co., Ltd. (“Xuanzhu Biology”), a non-wholly-owned subsidiary of the Group, has been declared for marketing and accepted by China's National Drug Administration (“State Drug Administration”). The specific indications for this report are: It is suitable for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) positive for anaplastic lymphoma kinase (ALK). Dacitinib tablets submitted a marketing application for Xuanzhu Biotech and

Gelonghui FinanceMay 2 00:05 ET